Ann: PTX-200 High Overall Response in Ph2a Breast Cancer trial, page-32

Based on the numbers this would be on par for FDA approval which if numbers continue in Ph3 would likely be approved as a therapy. This strategy looks like PTX will not settle until they have explored FIrst in line - ie blockbuster potential. These results already look to be on track to exceed or match recent FDA approved second line therapies eg in AML. IMO the addition of a trial combining with hormone therapy is because the team are aiming for blockbuster first in line therapy results aka - https://endpts.com/why-wait-the-fda-stamps-an-ultra-fast-ok-on-a-her2-drug-expected-to-create-astrazenecas-next-blockbuster-franchise/

this strategy is better for patients